Last checked at 5 May 2011 12:54
| FOR IMMEDIATE RELEASE | 5 May 2011 |
OXFORD BIOMEDICA PLC
ANNUAL GENERAL MEETING AND BOARD CHANGES
Oxford, UK - 5 May 2011: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:
·; Resolution 6: to empower the Directors to allot equity securities, pursuant to section 551 of the Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £3,149,585 with a further aggregate nominal amount of £3,149,585 authorised in connection with a rights issue, or where applicable, other proportionate offer;
·; Resolution 7: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;
·; Resolution 8: to extend the Oxford BioMedica plc Share Option Scheme on its current terms for five years from 1 February 2012.
·; Resolution 9: to extend the Oxford BioMedica plc Long Term Incentive Plan on its current terms for five years from 1 February 2012.
·; Resolution 10: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days notice.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting our website at www.oxfordbiomedica.co.uk
Certified copies of the document setting out the above resolutions passed at the 2011 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (03 May 2011) there were 944,875,557 1p ordinary shares in issue, each carrying one vote per share.
Resolution |
Votes For | Votes at Chairman's Discretion | Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast | Result |
Ordinary resolutions | |||||||
1 | 366,724,525 | 286,462 | 1,792,205 | 183,015 | 10,529 | 368,996,736 | Passed |
2 | 365,388,618 | 293,062 | 1,792,205 | 414,743 | 1,108,108 | 368,996,736 | Passed |
3 | 366,724,408 | 286,801 | 1,792,205 | 157,081 | 36,241 | 368,996,736 | Passed |
4 | 366,736,464 | 288,111 | 1,792,205 | 153,492 | 26,464 | 368,996,736 | Passed |
5 | 366,658,614 | 293,401 | 1,792,205 | 230,670 | 21,846 | 368,996,736 | Passed |
6 | 365,267,950 | 286,801 | 1,792,205 | 366,397 | 1,283,383 | 368,996,736 | Passed |
8 | 351,435,346 | 290,183 | 1,792,205 | 349,446 | 15,129,556 | 368,996,736 | Passed |
9 | 366,415,760 | 290,183 | 1,792,205 | 377,604 | 120,984 | 368,996,736 | Passed |
Special resolutions | |||||||
7 | 366,346,547 | 278,363 | 1,792,205 | 494,941 | 84,680 | 368,996,736 | Passed |
10 | 364,696,687 | 287,818 | 1,792,205 | 2,200,628 | 19,398 | 368,996,736 | Passed |
As announced on 21 March 2011, at the AGM the Chairman, Dr Alan Kingsman, left the Board of Oxford BioMedica. Nick Rodgers, previously Non-Executive Director, Senior Independent Director and Deputy Chairman, has become Chairman.
In addition to these changes, Dr Andrew Heath, Non-Executive Director, will now become the Senior Independent Director and Deputy Chairman.
-Ends-
For further information, please contact: | |
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications |
Tel: +44 (0)1865 783 000 |
Media/Financial Enquiries: Katja Toon/Emma Thompson/Amber Bielecka M:Communications |
Tel: +44 (0)20 7920 2342
|
Notes to editors
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.